Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a move that could significantly expand patient access in one of the world’s largest pharmaceutical markets. The price adjustment comes as China faces steadily rising obesity rates and growing demand for effective weight-loss treatments.
Novo Nordisk confirmed that it has begun adjusting the prices of Wegovy in China, although the company did not disclose a full breakdown of the new pricing structure. According to Chinese business news outlet Yicai, list prices for the two highest dosages of Wegovy have been reduced by as much as 48% in certain provinces. Under the reported changes, the monthly cost for these dosages has fallen to approximately 987 yuan ($141) and 1,284 yuan ($183), marking a substantial decrease compared with previous pricing.
In a statement, Novo Nordisk said the price reduction is aimed at easing the financial burden on patients and improving overall treatment accessibility. The company emphasized that the pricing adjustment aligns with its broader commitment to addressing chronic diseases such as obesity and supporting better long-term health outcomes for patients.
Chinese drug suppliers have also indicated that Eli Lilly’s obesity treatment, Mounjaro, is seeing similar price adjustments, although detailed figures have not been officially confirmed. Both Wegovy and Mounjaro are part of a new generation of GLP-1-based medications that have gained global attention for their effectiveness in weight management and metabolic health.
The price cuts could have a meaningful impact in China, where obesity and related conditions such as type 2 diabetes and cardiovascular disease are becoming more prevalent due to lifestyle changes and urbanization. Lower prices may encourage more patients to seek medical treatment rather than relying solely on diet or unregulated supplements.
For Novo Nordisk and Eli Lilly, reducing prices in China may also help strengthen their competitive positions as domestic pharmaceutical companies accelerate development of similar weight-loss drugs. Overall, the move highlights how global drugmakers are adapting pricing strategies to local markets while responding to rising demand for obesity treatments worldwide.
